<DOC>
	<DOC>NCT00845429</DOC>
	<brief_summary>Primary Objective: To describe the immune response to a single administration of 2 formulations of the investigational cell-based influenza vaccines in healthy adult subjects. Secondary Objective: To describe the safety following a single administration of 2 formulations of the investigational cell-based influenza vaccines in healthy adult subjects.</brief_summary>
	<brief_title>Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects</brief_title>
	<detailed_description>This is a multi-center study in healthy adult subjects. All subjects will receive a single dose of one of the influenza vaccine formulations and will provide blood samples for immunogenicity assessment.</detailed_description>
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Healthy male or female subject, aged ≥ 18 to &lt; 50 years on the day of inclusion Informed consent form signed Able to attend all scheduled visits and to comply with all trial procedures For a woman of childbearing potential: a negative urine pregnancy test and documented use of an effective method of contraception or abstinence for at least four weeks pre vaccination and up until three weeks postvaccination Exclusion Criteria : Subject currently breastfeeding. Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the trial vaccination. Planned participation in another clinical trial during the present trial period. Prior participation in the Phase I trial of FLU INTERPAN (PER.C6) vaccine (study GCE01). Congenital or history of acquired immunodeficiency, or immunosuppressive therapy such as anticancer chemotherapy or radiation therapy within the preceding 6 months. Systemic corticosteroid therapy as except the use of topical or inhalant corticosteroids Systemic hypersensitivity to egg proteins, chicken proteins, or to any of the vaccine components, or history of a lifethreatening reaction to the trial vaccine or a vaccine containing the same substances. Chronic illness at a stage that could interfere with trial conduct or completion (chronic illness may include, but is not limited to, cardiac, renal or autoimmune disorders, or diabetes). Receipt of blood or bloodderived products in the 3 months preceding vaccination. Receipt of any vaccination in the 4 weeks preceding vaccination, or planned receipt of any vaccination in the 4 weeks following the trial vaccination. History of influenza infection (confirmed either clinically, serologically or microbiologically) within the 6 months preceding vaccination. Previous vaccination against influenza (in the 6 months preceding the trial vaccination). Planned receipt of any other 20072008 influenza vaccine. Thrombocytopenia or bleeding disorder contraindicating intramuscular (IM) vaccination. Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent. History of GuillainBarré syndrome Current abuse of alcohol or drug addiction that may interfere with the subject's ability to comply with trial procedures Any other condition which in the opinion of the investigator would pose a health risk to the participant or interfere with the evaluation of the vaccine.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Orthomyxoviruses</keyword>
	<keyword>Split-virion inactivated influenza vaccine</keyword>
	<keyword>cell-based vaccine</keyword>
	<keyword>Adults</keyword>
</DOC>